3598 J ournal of Medicinal Chemistry, 2004, Vol. 47, No. 14
Fujita et al.
(20) Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Salvadori, S. What
peptides these deltorphin be. Prog. Neurobiol. 1999, 57, 377-
420.
(21) Podlogar, B. L.; Paterline, M. G..; Ferguson, D. M.; Leo, G. C.;
Demeter, D. A.; Brown, F. K.; Reitz, A. B. Conformational
analysis of the endogenous µ-opioid agonist endomorphin-1 using
NMR spectroscopy and molecular modeling. FEBS Lett. 1998,
439, 13-20.
(22) In, Y.; Minoura, K.; Ohishi, H.; Minakata, H.; Kamigauchi, M.;
Sugiura, M.; Ishida, T. Conformational comparison of µ-selective
endomorphin-2 with its C-terminal free acid in DMSO solution,
by 1H NMR spectroscopy and molecular modeling calculation.
J . Peptide Res. 2001, 58, 399-412.
(23) Keller, M.; Boissard, C.; Patiny, L.; Chung, N. N.; Lemieux, C.;
Mutter, M.; Schiller, P. W. Pseudoproline-containing analogues
of morphiceptin and endomorphin-2: evidence for a cis Tyr-Pro
amide bond in the bioactive conformation. J . Med. Chem. 2001,
44, 3896-3903.
(24) Yamazaki, T.; Probstl, A.; Schiller, P. W.; Goodman, M. Biological
and conformational studies of [Val4]morphiceptin and [D-Val4]-
morphiceptin analogs incorporating cis-2-aminocyclopentane
carboxylic acid as a peptidomimetics for proline. Int. J . Peptide
Res. 1991, 37, 364-381.
(25) Dygos, J . H.; Yonan, E. E.; Scaros, M. G.; Goodmonson, O. J .;
Getman, D. P.; Periana, R. A.; Beck, G. R. A convenient
asymmetric synthesis of the unnatural amino acid 2,6-dimethyl-
L-tyrosine. Synthesis 1992, 8, 741-743.
(26) Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.;
Crescenzi, O.; Guessiini, R.; Picone, D.; Tancredi, T.; Temussi,
P. A.; Lazarus, L. H. δ Opioidmimetic antagonist: prototypes
for designing a new generation of ultraselective opioid peptides.
Mol. Med. 1995, 1, 678-679.
(27) Bryant, S. D.; Salvadori, S.; Cooper, P. S.; Lazarus, L. H. New
δ-opioid antagonists as pharmacological probes. Trends. Phar-
macol. Sci. 1998, 19, 42-46.
Refer en ces
(1) Abbreviations used in this report for amino acids, peptide, and
their derivatives are those recommended by IUPAC-IUB Com-
mission on Biochemical Nomenclature: Biochemistry 1966, 5,
2485-2489; 1966, 6, 362-364; 1972, 11, 1726-1732. The
customary L-configuration for amino acid residues is omitted.
The following additional abbreviations are used: AcOEt, ethyl
acetate; AcOH, acetic acid; AD, adamantine; Boc, tert-butyloxy-
carbonyl; Bu, butyl; Bzl, benzyl; DADLE, [D-Ala2,D-Leu5]-
enkephain; DAMGO, Tyr-D-Ala-Gly-N-MePhe-Gly-ol; DIPEA,
N,N-diisopropylethylamine; DMF, N,N-dimethylformamide;
DMSO, dimethyl sulfoxide; Dmt, 2′,6′-dimethyl-L-tyrosine; DP-
DPE, Tyr-c(D-Pen-Gly-Phe-D-Pen); EDTA, ethylenediaminetet-
raacetic acid; EM-2, endomorphin-2; Et3N, triethylamine; Et2O,
diethyl ether; GPI, guinea pig ileum; HX, hexane; IBCF, isobutyl
chloroformate; Isq, isoquinoline; MeOH, methanol; MVD, mouse
vas deference; NMM, N-methylmorpholine; NMR, nuclear mag-
netic resonance; NOE, nuclear Overhauser effect; NOESY, nu-
clear Overhauser and exchange spectroscopy; Nph, naphthalene;
Ph, phenyl; PyBop, benzotriazol-1-yloxytris(pyrrolidino)phos-
phonium hexafluorophosphate; Pyr, pyridine; Qln, quinoline;
TFA, trifluoroacetic acid; THF, tetrahydrofuran; Z, benzyloxy-
carbonyl.
(2) Martin, W. R.; Eades, C. G.; Thompson, J . A.; Huppler, R. E.;
Gilbert, P. E. The effect of morphine- and morphine-like drugs
in the nondependent and morphine-dependent chronic spinal
dog. J . Pharmacol. Exp. Ther. 1976, 197, 517-532.
(3) Lord, J . A. H.; Waterfield, A. A.; Hughes, J .; Kosterlitz, H. W.
Endogenous opioid peptides: multiple agonists and receptors.
Nature 1977, 267, 495-499.
(4) (a) DeLander, G. E.; Portoghese, P. S.; Takemori, A. E. Role of
spinal mu opioid receptors in the development of morphine
tolerance and dependence. J . Pharmacol. Exp. Ther. 1984, 231,
91-96. (b) Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.;
Takemori, A. E. Selective blockage of delta opioid receptors
prevents the development of morphine tolerance and dependence
in mice. J . Pharmacol. Exp. Ther. 1991, 258, 299-303.
(5) Zadina, J . E.; Hackler, L.; Ge, L. J .; Kastin, A. J . A potent and
selective endogenous agonist for the mu-opiate receptor. Nature
1997, 386, 499-502.
(6) Hackler, L.; Zadina, J . E.; Ge, L. J .; Kastin, A. J . Isolation of
relatively large amounts of endomorphin-1 and endomorphin-2
from human brain cortex. Peptides 1997, 18, 1635-1639.
(7) Chang, K. J .; Killian, A.; Hazum, E.; Chang, J . K. Morphiceptin
(Tyr-Pro-Phe-Pro-CONH2): A potent and specific agonist for
morphiceptin (µ) receptors. Science 1981, 212, 75-77.
(8) Brantl, V.; Gramsch, C.; Lottspeich, F.; Mertz, R.; J aeger, K.
H.; Herz, A. Novel opioid peptides derived from hemoglobin:
hemorphins. Eur. J . Pharmacol. 1986, 125, 309-310.
(9) Horvath, A.; Kastin, A. J .; Isolation of tyrosine-melanocyte-
stimulating hormone releasing factor 1 from bovine tissue. J .
Biol. Chem. 1989, 264, 2175-2179.
(10) Horvath, A.; Kastin, A. J . Evidence for presence of Tyr-MIF-1
(Tyr-Pro-Leu-Gly-NH2) in human brain cortex. Int. J . Pept.
Protein Res. 1990, 36, 281-284.
(11) Echergyi, J .; Kastin, A. J .; Zadina, J . E. Isolation of a novel
tetrapeptide with opiate and antiopiate activity from human
brain cortex: Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1). Peptides
1992, 13, 623-631.
(12) Hackler, L.; Kastin, A. J .; Echergyi, J .; Zadina, J . E. Isolation
of Tyr-W-MIF-1 from bovine hypothalami. Neuropeptides 1993,
24, 159-164.
(13) Hughes, J .; Smith, T. W.; Kosterlitz, H. W.; Forthergill, L. A.;
Morgan, B. A.; Morris, H. R. Identification of two related
pentapeptides from the brain with potent opiateagonist activity.
Nature 1975, 258, 577-580.
(28) Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Guerrini, R.; Balboni,
G.; Salvadori, S. Design of δ-opioid peptide antagonists for
emerging drug applications. Drug Discovery Today 1998, 3, 284-
294.
(29) Sasaki, Y.; Suto, T.; Ambo, A.; Ouchi, H.; Yamamoto, Y.
Biological properties of opioid peptides replacing Tyr at position
1 by 2,6-dimethyl-Tyr. Chem. Pharm. Bull. 1999, 47, 1506-1509.
(30) Okada, Y.; Fujita, Y.; Motoyama, T.; Tsuda, Y.; Yokoi, T.; Li, T.;
Sasaki, Y.; Ambo, A.; J insmaa, Y.; Bryanat, S. D.; Lazarus, L.
H. Structural studies of [2′,6′-dimethyl-L-tyrosine1]-endomor-
phin-2 analogues: enhanced activity and cis orientation of Dmt-
Pro amide bond. Bioorg. Med. Chem. 2003, 11, 1983-1994.
(31) Balboni, G.; Salvadori, S.; Guerrini, R.; Bianchi, C.; Santagada,
V.; Calliendo, G.; Bryant, S. D.; Lazarus, L. H. Opioid pseudopep-
tides containinig heteroaromatic or heteroaliphatic nuclei. Pep-
tides 2000, 21, 1663-1671.
(32) Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.;
Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic
pharmacophore: Conversion of a potent δ-opioid receptor an-
tagonist into a potent δ-agonist and ligands with mixed proper-
ties. J . Med. Chem. 2002, 45, 713-720.
(33) Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.;
J insmaa, Y.; Bryant, S. D.; Lazarus, L. H. Potent δ-opioid
receptor agonists containig the Dmt-Tic Pharmacophore. J . Med.
Chem. 2002, 45, 5556-5563.
(34) Ishii, S.; Witkop, B.; Gramicidin, A. I. Determination of composi-
tion and amino acid configuration by enzymatic and gas chro-
matographic methods. J . Am. Chem. Soc. 1963, 85, 1832-1834.
(35) Goldschmidt, S.; Lautenschlager, H. Zur Darstellung Optisch-
aktiver Dipeptide nach der Phosphorazomethode (The synthesis
of optically active dipeptide by the phosphazo method). Chem.
Ber. 1958, 91, 449-455.
(14) Ling, N.; Burgus, R.; Guillemin, R. Isolation, primary structure
and synthesis of R-endorphin and γ-endorphin, two peptides of
hypothalamic-hypophysial origin with morphinomimetic activ-
ity. Proc. Natl. Acad. Sci. U.S.A. 1976, 73, 3042-3046.
(15) Cox, B. M.; Goldstein, A.; Li, C. H. Opioid activity of a peptide,
â-lipotorphin-(61-91), derived from â-lipotorphin. Proc. Natl.
Acad. Sci. U.S.A. 1976, 73, 1821-1823.
(16) Goldstein, A. G..; Fischil, W.; Lowney, L. I.; Hunkapilier, M.;
Hood, L. Porcine pituitary dynorphin: complete amino acid
sequence of biological active heptapeptide. Proc. Natl. Acad. Sci.
U.S.A. 1981, 78, 7219-7223.
(36) Vughan, J . R.; Osato, R. L. The preparation of peptides using
mixed carbonic-carboxylic acid anhydrides. J . Am. Chem. Soc.
1952, 74, 676-678.
(37) Honzl, J .; Rudinger, J . Nitrosyl chloride and butyl nitrite as
reagents in peptide synthesis by the azide method; suppression
of amide formation. Collect. Czech. Chem. Commun. 1961, 26,
2333-2344.
(38) Coste, J .; Le-Nguyn, D.; Castro, B. PyBOP: A new peptide
coupling reagent devoid of toxic by-product. Tetrahedron Lett.
1990, 31, 205-208.
(39) Temussi, P. A.; Salvadori, S.; Amodeo, P.; Bianchi, C.; Guerrini,
R.; Tomatis, R.; Lazarus, L. H.; Picone, D.; Tancredi, T. Selective
opioid dipeptides. Biochem. Biophys. Res. Commun. 1994, 198,
933-939.
(40) Capasso, A.; Guerrini, R.; Balboni, G.; Sorrentino, L.; Temussi,
P. A.; Lazarus, L. H.; Bryant, S. D.; Salvadori, S. Dmt-Tic-OH,
a high selective and potent δ opioidmimetic receptor antagonist
after systemic administration in the mouse. Life Sci. 1996, 59,
PL93-PL98.
(17) Handa, B. K.; Land, A. C.; Lord, J . A.; Morgen, B. A.; Rance, M.
J .; Smith, C. F. Analogues of beta-LPH61-64 possessing selective
agonist activity at mu-opiate receptors. Eur. J . Pharmacol. 1981,
70, 531-540.
(18) Schulz, R.; Wuster, M.; Krenss, H.; Herz, A. Selective develop-
ment of tolerance without dependence in multiple opiate recep-
tors of mouse vas deferens. Nature 1980, 285, 242-243.
(19) Melchiori, P.; Negri, L. The dermorphin peptide family. Gen.
Pharmacol. 1996, 27, 1099-1107.